在急性髓性白血病中EZH2的表观遗传作用
Jinyong Fang1, Jingcheng Zhang1, Lujian Zhu2
1Department of Hematology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang, China.
向 增强质同源2 (EZH2) 显示为治疗急性髓性白血病 (AML) 的前景. EZH2在AML进展中起着关键作用,抑制它可能提供一种新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 血液学 血液学 血液学
背景情况:
- 急性髓性白血病 (AML) 是一种异质的骨髓恶性瘤,其特征是髓性原始细胞扩张和阻断分化.
- 增强性基因同类2 (EZH2) 酶,是Polycomb Repressive Complex 2 (PRC2) 的一部分,通过基因组H3 lysine 27三甲基化 (H3K27me3) 通过表观遗传学调节基因表达.
- 失调的EZH2表达与包括AML在内的各种癌症有关,有助于瘤发生.
研究的目的:
- 审查EZH2在急性髓性白血病的发病过程中的多方面的作用.
- 探索EZH2抑制剂在AML治疗策略中的治疗潜力.
主要方法:
- 文献综述侧重于EZH2在AML中的功能.
- 分析EZH2在关键癌症特征中的参与:干性,增殖,分化,免疫反应,药物耐药性和复发.
- 目前在AML中的EZH2抑制剂应用和组合疗法的摘要.
主要成果:
- EZH2在调节AML的干性,增殖,分化,免疫逃避,耐药性和复发方面发挥着关键作用.
- 正在研究EZH2抑制剂作为AML的治疗方法.
- 涉及EZH2抑制剂的组合疗法显示了增强疗效的潜力.
结论:
- EZH2是急性髓性白血病进展和维持的重要驱动因素.
- 向EZH2代表了AML的一个有前途的新疗法策略.
- 对EZH2抑制的进一步研究,特别是在组合疗法中,对于AML治疗是有必要的.
更多相关视频
10:26Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
Published on: January 16, 2015
09:16Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019
相关概念视频
Master Transcription Regulators
Epigenetic Regulation
Histone Modification
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
Spreading of Chromatin Modifications
Writers
The writer...
Abnormal Proliferation
Chromatin Modification in iPS Cells
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
